EP3223832A1 - Verfahren zur herstellung von augentropfen - Google Patents
Verfahren zur herstellung von augentropfenInfo
- Publication number
- EP3223832A1 EP3223832A1 EP16711274.7A EP16711274A EP3223832A1 EP 3223832 A1 EP3223832 A1 EP 3223832A1 EP 16711274 A EP16711274 A EP 16711274A EP 3223832 A1 EP3223832 A1 EP 3223832A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- serum
- eye drops
- blood
- eye
- location
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0272—Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Definitions
- the present invention relates to a method of producing eye drops, the eye drops thus obtained, and a kit comprising the eye drops.
- the dry eye is one of the most common diseases in the field of ophthalmology, with the prevalence increasing with age.
- the dry eye is a multifactorial, as defined by the Dry Eye Workshop Study Group (DEWS Steering Committee)
- Keratoconjunctivitis sicca refers to an ocular surface disorder associated with typical symptoms such as foreign body sensation, photosensitivity, itching, burning pain and pressure sensation. In addition, vision loss, reddened eyes, epiphora (drenching), and dry eye sensation are often observed. With reduced tear production, the symptoms preferably occur in the morning. Lies the problem of increased tear fluid evaporation is more frequently mourned in the evening.
- Eye gel or eye spray offered.
- aqueous solutions of thickening agents such as, for example, povidone, hyproxymellose or carboxymethylcellulose, salts and optionally other active substances, such as hyaluronic acid or lipids, may be mentioned here.
- thickening agents such as, for example, povidone, hyproxymellose or carboxymethylcellulose, salts and optionally other active substances, such as hyaluronic acid or lipids, may be mentioned here.
- thickening agents such as, for example, povidone, hyproxymellose or carboxymethylcellulose, salts and optionally other active substances, such as hyaluronic acid or lipids
- Lipid layer of the tear film through a liposomal eye spray, which reduces the evaporation of the natural tear fluid and prevents premature drainage as a tear over the lid margin. Also known is the sentence of the tear film and the
- ointments are, in particular, oil in water emulsions.
- Punctum plaques are inserted into one or both puncta lacrimalia so that this outflow is reduced. Depending on the model, the plaques may remain permanently in the puncta lacrimalia or dissolve after a few weeks. The main disadvantage of this
- Procedure is that by retaining the tear fluid at the same time the inflammatory substances in the
- composition longer stay on the eye.
- the plaque-induced drainage of tear fluid through the draining lacrimal ducts may also promote infection by bacteria that may emerge from the nasal cavity.
- Ocular surface is the use of eye drops from serum
- Autologous Serum Eye Drops ", Inaugural Dissertation University of Er Weg Nuremberg, December 20, 2012)
- Autologous serum means autologous serum obtained from the blood of the person who later uses the eye drops prepared therefrom.
- Thawed bottles should be stored at + 2 ° C to + 6 ° C for a maximum of one week.
- the high proportion of proteins in the serum causes a microbial reaction
- the method further comprises step e) Final examinations before the release of eye drops as a drug for sterility.
- identity and / or purity can also be checked during the final examination.
- Ready-to-use eye drops for the purposes of the present invention are those eye drops that can be used directly by people.
- the delivery of serum eye drops is a
- Blood collection bag is directly connected to the administration means. Carrying out the blood collection in one place, for example the blood donation service, and the filling of the serum in a second one, according to the legal prescription in a pharmacy, make it possible to deliver the eye drops in a pharmacy, for example near the place of residence or near the place of residence
- the removal of larger amounts of blood than 100 ml or more than 200 ml, for example of 500 ml, is preferably carried out as part of a whole blood donation.
- blood or whole blood is meant the blood, which contains all native components.
- Blood donation centers are removed. A whole blood donation, at the about 500 ml of blood can be withdrawn after its
- the withdrawal of 500 ml of blood corresponds to the amount of blood that is usually taken during a whole blood donation.
- the removal of more than 500 ml of blood and the further processing to eye drops from self-serum is possible in principle.
- the whole blood may be autologous or allogeneic whole blood.
- Autologous whole blood means that the eye drops taken from the serum are used exclusively by the person who has also donated the blood.
- allogeneic whole blood blood donors and users of the eye drops are different persons.
- the use of autologous whole blood has the advantage that only
- the separation of the blood into its blood components is carried out by coagulation. This is preferably done over a period of 15 minutes to 70 minutes at room temperature.
- Room temperature for the purposes of the present invention is a temperature in the range of 15 ° C to 30 ° C, in particular from 18 ° C to 25 ° C.
- Coagulation is the coagulation of blood. This leads to a separation of the blood components. After coagulation it is
- the blood at + 2 ° C to + 8 ° C.
- Storage may be overnight, for example, but should not exceed 48 hours due to the microbial susceptibility of the serum.
- an enzymatic degradation of the blood components begins after about 48 hours.
- one is Storage of 12 to 48 hours preferred because it can be ensured that the coagulation is complete.
- centrifugation of the blood which has already been at least partially separated by coagulation, takes place.
- the centrifugation is preferably carried out over a period of 5 to 20 minutes, in particular from 5 to 15 minutes, at 1000 to 3500 revolutions / min, in particular at 1000 to 3000 revolutions / min.
- This is preferably an empty blood bag (empty bag, serum bag), which can be welded to the blood bag containing the separated blood via a connecting tube. As a result, contamination of the serum by external influences can be almost avoided.
- the physiological serum osmolarity (isotonia) in humans is usually 281 to 297 mosmol / l. This value corresponds to that of tear fluid, which results in the preferred use of self-serum eye drops in the treatment of ocular diseases and in particular of
- the recovered serum is in suitable before filling
- pathogens are factors which trigger or favor infectious agents or other diseases which may adversely affect the human organism and, especially when used as eye drops, could jeopardize therapeutic success or
- Contaminations of the serum may, for example, also occur during the blood collection or the separation of the blood.
- a corresponding examination of the blood can also take place according to the invention even before the blood sample is taken. This is also recommended because in the presence of contaminants, the blood can be discarded for the preparation of eye drops.
- the re-examination of the serum according to the invention provides additional security in order to ensure improved product safety. It is possible according to the invention to store the serum before filling in an administration agent at a temperature of - 20 ° C. In this case, the testing for contaminants preferably takes place after storage and immediately before filling in the administering agent.
- the serum is in particular up to the presence of the findings of the infection examination in a temperature-controlled Refrigerator intermediately stored. Are the infection tests negative?
- Dispensing agent be bottled.
- step d) is preferably done in a clean room. This can be the
- Administering agent It should be noted that during transport, the temperature of 10 ° C, in particular of 8 ° C is not exceeded.
- inventive method allows a location-independent production of Eigenserumaugentropfen, which causes the more flexible application of the method according to the invention. If there is a long way to go for blood collection and preservation of the eye drops for the end user, this also often leads to lower compliance for him. With the method according to the invention, it is now possible that a whole blood donation, for example in a
- the transport of the serum for example, in a pharmacy, which preferably has a clean room.
- the serum can then be filled and delivered in single doses to the patient.
- the clean room is located near the place where blood is collected. Here can be done after filling in the delivery of the transport to a local pharmacy.
- inventive method thus allows an extremely high flexibility, which leads to a near-residential care of the patient with Eigenserumaugentropfen.
- the method preferably comprises the following steps:
- the method comprises the following steps:
- the filling of the serum in the administering agent can be carried out in a simple manner, for example by means of a three-way stopcock.
- Three-way stopcock is thereby connected with a connection to a bag in which the serum is located (serum bag).
- serum bag a bag in which the serum is located
- Corresponding bags usually have a hose to which the
- Three-way cock can be connected.
- Connection of the three-way valve can then be connected to the administering agent.
- the position of the cock then controls the filling of the serum into the administering agent.
- Allow filling of the administering agent is not preferred, as it leads to cross contamination between the Serum batches can come.
- another administration container is connected to the three-way cock.
- inventive method allows the receipt of a large
- the filling preferably takes place in a clean room. This avoids further infection of the serum.
- Suitable administration containers are known in the art.
- a possible administration container which is described in DE 20 2011 004 487 Ul, comprises a collecting and
- Venting container which via an end line with the
- Administration containers are each provided with opening means and are connected by flow.
- Delivery containers can be connected by means of a sterile piece of tubing to the serum bag, for example by means of a three-way stopcock.
- the individual administration containers each have a volume of about 3 ml.
- Administering containers are interconnected, a volume which collects serum that is not available for use as self-serum dew drops (dead volume).
- the individual administration containers are also made of one
- volumes that are used for the therapy and the duration of treatment can not be predicted.
- the large opening carries a high risk of contamination of the bottle contents, for example with bacteria or fungi.
- shelf life of each administration container is the amount of eye drops that is available, compared to the
- the administration container is a pumping system which comprises a container for receiving the eye drops and a pumping device for metering the eye drops into the eye.
- the pumping system is designed so that it is suitable for multiple use. The amount of eye drops contained therein is sufficient, for example, to provide a supply of eye drops over a
- a pumping system is then delivered to the patient, the others are preferably stored at the second location, ie in particular in the pharmacy, with cooling. If necessary, the eye drops are then delivered to the patient
- the pumping device may also be a
- antibacterial device such as a silver spiral
- antibacterial device such as a silver spiral
- Corresponding pump systems are described, for example, in EP 1 380 351 A1.
- the method comprises the following steps:
- the administration means is a pumping system comprising a container for receiving the eye drops and a container
- the filling of the serum takes place in that preferably removed in a clean room under sterile conditions by means of a sterile syringe serum from the serum bag and the multidose drip system (dosing) is filled with pumping system with 5 ml.
- the attachments of the dosing bottles are placed manually, a sleeve added to protect against breaking the bottles and sealed by operating a lifting press firmly with the bottle.
- the filter contained in the dosing bottle or the pumping system protects the serum from microbiological contamination. A silver spiral in the tip prevents that
- the advantage here is that the self-serum eye drops can be stored over a longer period of at least 7 days for the patient in the refrigerator, ie at a temperature of + 2 ° C to + 8 ° C, or even at room temperature without contamination with aerobic or anaerobic bacteria or fungi.
- contact with the silver spiral in the dosage of the eye drops they are kept substantially free of microbes.
- Gelichzeitig is the
- the serum after filling in suitable administration containers at a temperature of T ⁇ -20 ° C is stored.
- Temperature of + 4 ° C to + 8 ° C, or at room temperature can be handed over for at least 7 days. Thus, even such persons over a long
- Periods are supplied with serum eye drops in which a blood sample, for example, due to health problems is not or only rarely possible.
- Administration containers is diluted.
- This dilution can be carried out, for example, by means of known artificial tear replacement agents which comprise, for example, isotonic saline solution and / or active substances such as hyaluronic acid and / or lipids.
- the dilution may be in the range of 10% to 30%. This means for the purposes of the present invention that based on 100 wt .-% of eye drops, these consist of 90 wt .-% of serum and 10 wt .-% of tear substitute.
- a dilution of 20% by weight means that the eye drops consist of 80% by weight of serum and 20% by weight of tear substitution, and a dilution of 30% by weight that the eye drops consist of 70% by weight of serum and 30 wt% tear substitutes.
- the dilution of the serum eye drops allows a supply of affected persons over a period of approximately one year or depending on the frequency of use also beyond, which also results in improved compliance.
- protein deposits can occur in the eye when undiluted serum eye drops are used become. By a dilution according to the invention such protein deposits can be avoided.
- Illness can not go back to blood. This may, for example, be the case with a leukemia disease in which stem cells have been transplanted for therapy. Affected patients are at risk of developing a "graft versus host desease" due to an immune response to the transplanted stem cells, which is already among those already diagnosed
- corneal lesions can come in the eye. These can also be well treated with serum eye drops. However, regular blood sampling can not be ensured here due to the disease.
- inventive method can come in the eye. These can also be well treated with serum eye drops. However, regular blood sampling can not be ensured here due to the disease.
- the dilution should not exceed a value of 30%. At a higher dilution, the flow properties of the eye drops change, so that a good adhesion to the eye is no longer present.
- the other properties such as the protein concentration, are influenced in such a way that the positive properties of the Serumaugentropfen opposite
- the serum contained therein is re-examined for the presence of diseases and / or infections. Since, according to the invention, a larger amount of blood is taken at the beginning, there is one
- the present invention further relates to eye drops, which after the inventive
- eye drops are suitable for the treatment of dry
- hormone preparations for example, hormone preparations, beta-blockers or psychotropic drugs, occur.
- Chemotherapeutic agents can be treated with the eye drops of the invention.
- the eye drops are not only suitable for illness-related dry eyes, but can also be used by people who work a lot on the computer or because of the workplace in particularly dry, cold rooms.
- the present invention relates to a kit which the
- Eye drops in a suitable administration container includes.
- Eye drop An administration container which comprises a pump system which has a container for receiving the eye drops and a pump device for metering the eye drops, is preferred, since here the quantity of eye drops which occurs in the case of the eye drops
- Blood collection tubes have no coagulation inhibitors (ACD: acid citrate dextrose), so that the blood in the inventive Method can be used. After blood collection, coagulation was carried out at room temperature in standing tubes.
- ACD acid citrate dextrose
- Coagulation was complete when the blood cake containing the solid components of the blood could be detached from the vessel wall with a spatula. This could be done after 20 to 30 minutes.
- the serum contained therein was centrifuged at 3500 rpm for 20 minutes. Immediately thereafter, the serum supernatant was pipetted off and the resulting serum stored in the refrigerator at a temperature of 4 ° C to 8 ° C.
- the serum was in administration vessels pumping system as described by the company Aero Pump GmbH as a eye dropper system with 3K ® -
- Example AT 1 5 ml serum in the administration vessel
- Example AT 2 5 ml serum eye drops (10% dilution with
- Example AT 3 5 ml serum eye drops (20% dilution with
- Example AT 4 5 ml serum eye drops (30% dilution with
- a dilution of 10% means that 90% by weight of the
- Serum eye drops are serum and 10% by weight isotonic saline. The same applies to the other dilutions.
- the ready-to-use eye drops were stored in the refrigerator at a temperature of 4 ° C to 8 ° C. Samples were taken 5 times daily over a period of 9 days from the respective eye drops ATI to AT 4.
- Embodiment 2 is a diagrammatic representation of Embodiment 1:
- the serum was transported at + 4 ° C in a clean room (class A in B). There, the filling of the serum took place in
- Example AT 5 Serum before filling in the administration vessel
- Example AT 6 Serum in pump system after 48 h storage at -20 ° C.
- Example AT 7 Serum in pump system after 48 h storage at +4 ° C to +8 ° C
- Example AT 8 Serum in pump system after 48 h storage at
- Example AT 9 Serum in pumping system after 5 days storage at room temperature (20 ° C)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102015205293.1A DE102015205293A1 (de) | 2015-03-24 | 2015-03-24 | Verfahren zur Herstellung von Augentropfen |
PCT/EP2016/056197 WO2016150932A1 (de) | 2015-03-24 | 2016-03-22 | Verfahren zur herstellung von augentropfen |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3223832A1 true EP3223832A1 (de) | 2017-10-04 |
Family
ID=55588284
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16161494.6A Ceased EP3081220A1 (de) | 2015-03-24 | 2016-03-22 | Verfahren zur herstellung von augentropfen |
EP16711274.7A Ceased EP3223832A1 (de) | 2015-03-24 | 2016-03-22 | Verfahren zur herstellung von augentropfen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16161494.6A Ceased EP3081220A1 (de) | 2015-03-24 | 2016-03-22 | Verfahren zur herstellung von augentropfen |
Country Status (4)
Country | Link |
---|---|
US (1) | US10300088B2 (de) |
EP (2) | EP3081220A1 (de) |
DE (1) | DE102015205293A1 (de) |
WO (1) | WO2016150932A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3471742A4 (de) * | 2016-06-16 | 2020-03-04 | Eye Care International, LLC | Zusammensetzungen und verfahren zur behandlung von trockenem auge und anderen traumatisierten nicht-keratinisierten epitheloberflächen |
WO2019213281A1 (en) * | 2018-05-01 | 2019-11-07 | David Muller | Eye treatments employing serum from whole blood |
US10800556B2 (en) * | 2018-10-25 | 2020-10-13 | Thorne Intellectual Property Holdings, Llc | Methods for preparing autologous blood eye drops |
US20230193206A1 (en) * | 2019-12-27 | 2023-06-22 | Sapporo Medical University | Method for Producing Serum for Culturing Mammalian Cells |
WO2022029113A1 (en) * | 2020-08-03 | 2022-02-10 | Sereye Gmbh | Composition for treating eye diseases and method of producing same |
EP4188545B1 (de) * | 2020-08-03 | 2024-01-31 | SerEye GmbH | Zusammensetzung zur behandlung von beschädigten epitheloberflächen und verfahren zu deren herstellung |
EP4309667A1 (de) * | 2022-07-18 | 2024-01-24 | Sanaplas GmbH | Produkt; das sich zur behandlung von tränenfilmmangel bei der krankheit des trockenen auges eignet, und ein verfahren zum herstellen des produkts |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2227684T3 (es) * | 1996-04-19 | 2005-04-01 | Sucampo Ag | Albumina como ingrediente activo para el tratamiento de lesiones conjuntivas y de la cornea y del ojo seco. |
US20030032930A1 (en) * | 2001-02-06 | 2003-02-13 | Vista Innovations, Inc. | Eye drop dispensing system |
DE10231749B4 (de) | 2002-07-13 | 2004-07-29 | Aero Pump GmbH, Zerstäuberpumpen | Saug-Druck-Pumpe zum Ausgeben einer Flüssigkeit aus einem Behältnis |
US20080299212A1 (en) * | 2005-02-25 | 2008-12-04 | Medigenes Co., Ltd | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum |
DE102009022793A1 (de) | 2009-05-27 | 2010-12-02 | Justus-Liebig-Universität Giessen | Vorrichtung und Verfahren zur Herstellung von Blutprodukten |
DE202011004487U1 (de) | 2011-03-28 | 2012-06-29 | Heinz Meise Gmbh | Vorrichtung zur Abfüllung von Blutprodukten |
ITMO20130001A1 (it) * | 2013-01-09 | 2014-07-10 | Biomed Device Srl | Metodo per il riempimento di contenitori con emocomponenti freschi autologhi |
BR112016004510A2 (pt) * | 2013-08-27 | 2017-09-12 | Cook General Biotechnology Llc | composições bioativas deriváveis de concentrados de plaquetas e métodos para preparar e usar as mesmas |
-
2015
- 2015-03-24 DE DE102015205293.1A patent/DE102015205293A1/de not_active Withdrawn
-
2016
- 2016-03-22 EP EP16161494.6A patent/EP3081220A1/de not_active Ceased
- 2016-03-22 EP EP16711274.7A patent/EP3223832A1/de not_active Ceased
- 2016-03-22 US US15/559,653 patent/US10300088B2/en active Active
- 2016-03-22 WO PCT/EP2016/056197 patent/WO2016150932A1/de active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US10300088B2 (en) | 2019-05-28 |
EP3081220A1 (de) | 2016-10-19 |
US20180050064A1 (en) | 2018-02-22 |
DE102015205293A1 (de) | 2016-09-29 |
WO2016150932A1 (de) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016150932A1 (de) | Verfahren zur herstellung von augentropfen | |
EP1984006B1 (de) | Konditionierte blutzusammensetzung und verfahren zu deren herstellung | |
KR102614858B1 (ko) | 안검염 치료에 사용되는 약제학적 조성물 | |
EP2435104B1 (de) | Vorrichtung und verfahren zur herstellung von blutprodukten | |
KR101176380B1 (ko) | 모낭충 감염증 치료를 위한 조성물 및 방법 | |
EP3335744B1 (de) | Verfahren zum herstellen einer leukozytenpräparation und leukozytenpräparation | |
EP3199163A1 (de) | Zusammensetzung von doxycyclin in liposomen zur prävention, verbesserung und/oder behandlung von augenerkrankungen | |
CN110269839A (zh) | 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用 | |
DE102011114459A1 (de) | Katheterblockbeutel | |
DE69830176T2 (de) | Arzneimittel gegen infertilität, die mit endometriose assoziiert ist | |
Russell et al. | The inclusion of antimicrobial agents in pharmaceutical products | |
CN104248645B (zh) | 一种复方聚维酮碘消毒液及其制备方法 | |
TWI714521B (zh) | 蜂蜜組合物 | |
Farida et al. | Production and characterization of vaginal suppositories with propolis wax as active agent to prevent and treat Fluor albus | |
KR100859156B1 (ko) | 유치 도뇨관 삽입환자의 회음부 간호용 아로마 에센셜 오일의 조성물 및 이를 이용한 회음부 처치도구 | |
DE60022988T2 (de) | Medikament gegen dysmenorrhoe und premenstruelles syndrom enthaltend lidocain | |
Rodrigues et al. | Feline eosinophilic keratoconjunctivitis: nonsteroidal vs corticosteroid topical treatment | |
DE102004018347A1 (de) | Wundheilungsfördende Botenstoffmischung | |
CN1143498A (zh) | 祛痘灵及其制备方法 | |
Garcia-Santisteban et al. | TOXICITY EVALUATION OF A NOVEL RAPAMYCIN LIPOSOMAL FORMULATION AFTER SUBCONJUNCTIVAL AND INTRAVITREAL INJECTION | |
Lin et al. | Comparative study of the disinfection effects of three types of conjunctiva sac irrigations | |
Teed | Sinus Complications of Colds | |
Kumar et al. | CLINICAL EUALUTION OF THE EFFICACY ON TARPAN KARMA IN DRY EYE SYNDROME WSR TO BLEPHARITIS (KRIMIGRANTHI) BY JIVANTIYADI GHRITTA USING FIUROSCEIN AND ROSE BENGAL CORNEAL STAINING | |
CH713095B1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Entzündungen. | |
Garg et al. | OPHTHALMIC DRUG DE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20170623 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CY CZ DE DK EE ES FI GB GR HR HU IE IS IT LT LU LV MC MK MT NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20181015 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20200207 |